Linavonkibart Pembrolizumab: Advanced Solid Tumors Trial
Competing interests
T.A.Y. reports consulting fees from 858 therapeutics, AbbVie, Acrivon, Adagene, Aeneid Therapeutics, Almac, Alterome Therapeutics, aduro Biotech, Amgen, Amphista Therapeutics, Artios, Astex, AstraZeneca, Atavistik, athena, Atrin Pharmaceuticals, Avenzo, Avoro, AXIOM, Baptist Health system, Bayer, BeiGene, Bicycle Therapeutics, BioCity Pharma, Bloom burton, Blueprint Medicines, Bluestar Bio, Boxer capital, BridGene Biosciences, Bristol Myers Squibb, C4 Therapeutics, Calithera Biosciences, Cancer Research Horizons, Cancer Research UK, carrick Therapeutics, Circle Pharma, Clasp, Clovis Oncology, Cybrexa Therapeutics, Daiichi-Sankyo, DAiNA, Dark Blue Therapeutics, Dawn Manco, debiopharm, Diffusion Pharmaceuticals, Duke Street Bio, EcoR1 Capital, Eikon, Ellipses Pharma, EMD Serono, Entos, Flagship Pioneering, Forbion, FoRx Therapeutics AG, F-Star Therapeutics, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, Gray Wolf Therapeutics, GlaxoSmithKline, Guardant, Guidepoint, IDEAYA Biosciences, Idience, ignyta, I-Mab, ImmuneSensor Therapeutics, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Janssen, Jazz Pharmaceuticals, Joint Scientific Committee for Phase I Trials in Hong Kong, Kyn Therapeutics, Kyowa Kirin Pharmaceutical Development, Lumanity, MEI Pharma, Mereo BioPharma, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexus Pharmaceuticals, Nimbus, Novocure, Odyssey Therapeutics, OHSU, OncoSec, Ono Pharmaceuticals, Onxeo, Pfizer, Piper-sandler, Pliant Therapeutics, plexium, Prelude Therapeutics, ProLynx, Protai Bio, PSIM, radiopharm Theranostics, Repare Therapeutics, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Stablix, synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2 Theragnostics, techspert.io, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Thryv Therapeutics, tolremo, Tome Biosciences, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome Therapeutics, vivace Therapeutics, Voronoi Inc, XinThera and Zai Labs. T.A.Y. also reports grant and research support from 858 Therapeutics, Accent, Aprea Therapeutics, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint Medicines, Bristol Myers squibb, Boundless Bio, BridGene BioScience, Circle Pharma, Clovis Oncology, Constellation, Cancer Prevention and Research Institute of Texas, Cyteir, US Department of Defense, eisbach Bio, Lilly, EMD Serono, Exelixis, Forbius, F-Star Therapeutics, Gilead, GlaxoSmithKline, Genentech, Golfers Against Cancer, Haihe Pharmaceutical, IDEAYA biosciences, ImmuneSensor Therapeutics, Insilico Medicine, Ionis, Ipsen, Jounce Therapeutics, Karyopharm, KSQ, kyowa kirin Pharmaceutical Development, Loxo Oncology, Merck, Mirati, Novartis, National Institutes of Health/National Cancer Institute, Pfizer, Pliant Therapeuticts, Prelude Therapeutics, Ribon Therapeutics, Regeneron, Repare Therapeutics, roche, Rubius Therapeutics, Sanofi, Scholar Rock, Seattle Genetics, SpringWorks, Synnovation, Tango, Tesaro, V Foundation, Vivace therapeutics, Zenith and Zental
Okay, I will process the provided text according to the instructions, focusing on adversarial research, freshness checks, entity-based geo, and the semantic answer rule.
PHASE 1: ADVERSARIAL RESEARCH, FRESHNESS & BREAKING-NEWS CHECK
The provided text details financial disclosures of individuals involved in a research context, likely a clinical trial or publication.The disclosures relate to consulting fees, research funding, advisory board memberships, employment, and stock ownership.I will verify the existence of these companies and individuals and check for any recent (as of 2026/01/13 18:43:31) important news related to their disclosures.
* Bayer: https://www.bayer.com/ – Still a major pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* biontech: https://www.biontech.de/en/ – still active, primarily known for mRNA vaccine technology.No major disclosure-related news as of 2026/01/13.
* Bristol Myers Squibb: https://www.bms.com/ – Still a major pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* Clinigen: https://www.clinigen.com/ – Acquired by Cencora in 2023.https://www.cencora.com/newsroom/press-releases/cencora-completes-acquisition-of-clinigen-group-plc/
* ConcertAI: https://www.concertai.com/ – Still operating as a real-world data and AI company for healthcare. No major disclosure-related news as of 2026/01/13.
* Eisai: https://www.eisai.com/en/ – Still a pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* genentech/Roche: https://www.gene.com/ & https://www.roche.com/ - Both still operating. No major disclosure-related news as of 2026/01/13.
* Instil Bio: https://www.instilbio.com/ – Still operating as a cell therapy company. no major disclosure-related news as of 2026/01/13.
* Merck: https://www.merck.com/ – Still a major pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* Novartis: https://www.novartis.com/ – Still a major pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* Partner Therapeutics: https://partnertherapeutics.com/ – Still operating. No major disclosure-related news as of 2026/01/13.
* Sanofi/Regeneron Pharmaceuticals: https://www.sanofi.com/ & https://www.regeneron.com/ – Both still operating. No major disclosure-related news as of 2026/01/13.
* Acrotech Biopharma: https://acrotechbiopharma.com/ – Still operating. No major disclosure-related news as of 2026/01/13.
* Agenus: https://www.agenusbio.com/ – Still operating. No major disclosure-related news as of 2026/01/13.
* InflaRx: https://www.inflarx.com/ – Acquired by Revive Therapeutics in 2023. https://www.revivetherapeutics.com/news-releases/news-release-details/revive-therapeutics-completes-acquisition-of-inflarx-inc/
* OncoSec: https://oncosec.com/ – No recent activity, appears to be defunct.
* Pfizer: https://www.pfizer.com/ – Still a major pharmaceutical company. No major disclosure-related news as of 2026/01/13.
* Scholar Rock: https://www.scholarrock.com/ – Still operating. No major disclosure-related news as of 2026/01/13.
* Aktis Oncology: https://aktisoncology.com/ - still operating. No major disclosure-related news as of 2026/01/13.
* Astellas Pharma: https://www.astellas.com/en/ – Still operating. No major disclosure-related news as of 2026/01/13.